Related Experiment Video
Updated: Nov 24, 2025
Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
Efficacy and safety of pasireotide for Cushing's disease: A protocol for systematic review and meta-analysis
Nairui Zhao1, Xinxin Yang, Cuiliu Li
1Second Department of Endocrinology, Cangzhou Central Hospital, Cangzhou, China.
Insights
This systematic review evaluates pasireotide, a medication for Cushing's disease (CD), assessing its effectiveness and safety. The findings will inform clinical practice and policy for managing this rare endocrine disorder.
Area of Science:
- Endocrinology
- Pharmacology
- Clinical Medicine
Background:
- Cushing's disease (CD) presents significant health risks, including mortality, cardiovascular events, and infections.
- Pharmacotherapy is a crucial option for CD when surgery is not viable.
- Pasireotide is the first approved medical therapy for adult CD patients.
Purpose of the Study:
- To systematically evaluate the efficacy and safety of pasireotide for Cushing's disease.
- To synthesize current published data on pasireotide's use in CD management.
Main Methods:
- Comprehensive systematic review and meta-analysis.
- Searched five English and three Chinese databases up to December 2020.
- Independent data extraction and risk of bias assessment by two reviewers, with third reviewer for disagreements.
Main Results:
- This systematic review and meta-analysis will synthesize published data on pasireotide for CD.
- The study aims to explore the efficacy and safety profile of pasireotide in treating CD.
Conclusions:
- This review will provide clinical evidence on pasireotide's efficacy and safety in Cushing's disease.
- Findings will enhance understanding of pasireotide's value in managing CD symptoms.
- Results may assist patients, clinicians, and policymakers in CD treatment decisions.
Background:
Cushing's disease (CD) is associated with increased risk of mortality, myocardial infarction, stroke, peptic ulcers, fractures and infections. The prevalence of CD is nearly 40 per million and higher in women than in men. When surgery has failed, is not feasible, or has been refused, pharmacotherapy can be considered a valuable option. Pasireotide is the first medical therapy officially approved for adult patients with CD. We will conduct a comprehensive systematic review and meta-analysis to systematically evaluate the efficacy and safety of pasireotide for CD.
Methods:
Five English databases (PubMed, Web of Science, Embase, Cochrane Library, and OVID) and 3 Chinese databases (China National Knowledge Infrastructure, China Science and Technology Journal Database, and Chinese Biomedical Literature Database) will be searched from their respective inception of databases to December 2020. Two reviewers will select articles, extract data and assess the risk of bias independently. Any disagreement will be resolved by discussion with the third reviewer. Review Manager 5.3 software will be used for data synthesis. The Cochrane risk of bias assessment tool will be used to evaluate the bias risk.
Results:
This systematic review and meta-analysis will conduct a comprehensive literature search and provide a systematic synthesis of current published data to explore the efficacy and safety of pasireotide for CD.
Conclusions:
This systematic review and meta-analysis will provide clinical evidence for the efficacy and safety of pasireotide for CD, and inform our understanding of the value of pasireotide in improving CD clinical signs and symptoms. The conclusions drawn from this study may be beneficial to patients, clinicians, and health-related policy makers.
Study Registration Number:
INPLASY2020110070.
Related Concept Videos
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
01:30Psychosurgery
Historical Development of Psychosurgery
In the 1930s, Portuguese neurologist Antonio Egas Moniz introduced a surgical procedure designed...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment: